Luzelena Caro

1.5k total citations
59 papers, 1.0k citations indexed

About

Luzelena Caro is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Luzelena Caro has authored 59 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hepatology, 30 papers in Infectious Diseases and 22 papers in Epidemiology. Recurrent topics in Luzelena Caro's work include Hepatitis C virus research (32 papers), HIV/AIDS drug development and treatment (25 papers) and Antibiotics Pharmacokinetics and Efficacy (10 papers). Luzelena Caro is often cited by papers focused on Hepatitis C virus research (32 papers), HIV/AIDS drug development and treatment (25 papers) and Antibiotics Pharmacokinetics and Efficacy (10 papers). Luzelena Caro collaborates with scholars based in United States, Japan and Germany. Luzelena Caro's co-authors include Richard B. Dickinson, Daniel L. Purich, Elizabeth G. Rhee, Kajal Larson, Brian Yu, S. Aubrey Stoch, Iain P. Fraser, Stephanie O. Klopfer, Matthew L. Rizk and Michael Robertson and has published in prestigious journals such as SHILAP Revista de lepidopterología, The EMBO Journal and Gastroenterology.

In The Last Decade

Luzelena Caro

56 papers receiving 986 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luzelena Caro United States	17	456	325	249	194	157	59	1.0k
Hwa-ping Feng United States	11	163 0.4×	181 0.6×	117 0.5×	58 0.3×	40 0.3×	38	573
Natsuo Tachikawa Japan	16	284 0.6×	64 0.2×	533 2.1×	48 0.2×	240 1.5×	74	999
Joaquin Valdes United States	16	453 1.0×	357 1.1×	1.1k 4.4×	54 0.3×	191 1.2×	31	2.6k
Paul Meyvisch Belgium	12	871 1.9×	234 0.7×	1.0k 4.2×	71 0.4×	73 0.5×	30	1.6k
S. James Matthews United States	14	230 0.5×	85 0.3×	84 0.3×	85 0.4×	61 0.4×	24	674
Isabelle Seguin Canada	11	278 0.6×	96 0.3×	229 0.9×	36 0.2×	99 0.6×	13	943
Margherita Macera Italy	17	627 1.4×	566 1.7×	111 0.4×	76 0.4×	60 0.4×	60	987
Jennifer L. Stotka United States	11	272 0.6×	155 0.5×	188 0.8×	86 0.4×	73 0.5×	17	756
Seok Hwee Koo Singapore	16	173 0.4×	27 0.1×	68 0.3×	49 0.3×	119 0.8×	49	702
Sanjay Kumar Kochar India	22	178 0.4×	99 0.3×	217 0.9×	48 0.2×	72 0.5×	60	2.0k

Countries citing papers authored by Luzelena Caro

Since Specialization

Citations

This map shows the geographic impact of Luzelena Caro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luzelena Caro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luzelena Caro more than expected).

Fields of papers citing papers by Luzelena Caro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luzelena Caro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luzelena Caro. The network helps show where Luzelena Caro may publish in the future.

Co-authorship network of co-authors of Luzelena Caro

This figure shows the co-authorship network connecting the top 25 collaborators of Luzelena Caro. A scholar is included among the top collaborators of Luzelena Caro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luzelena Caro. Luzelena Caro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Humeniuk, Rita, Deqing Xiao, Shuguang Chen, et al.. (2025). Clinical Evaluation of Drug–Drug Interactions with Obeldesivir, an Orally Administered Antiviral Agent. Clinical Pharmacology & Therapeutics. 117(5). 1403–1412.

Chang, Jack, Aryun Kim, Rita Humeniuk, et al.. (2025). Characterization of Drug–Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS‐CoV‐2, in Healthy Participants. Clinical and Translational Science. 18(11). e70395–e70395.

Abdelghany, Mazin, Amos Lichtman, Ran Duan, et al.. (2024). Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants. Clinical Pharmacology & Therapeutics. 116(5). 1231–1239. 3 indexed citations

Groll, Andreas H., Johannes H. Schulte, Bülent Antmen, et al.. (2024). Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients. The Pediatric Infectious Disease Journal. 43(3). 203–208. 16 indexed citations

Nicolau, David P., Jan J. De Waele, Joseph L. Kuti, et al.. (2021). Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. International Journal of Antimicrobial Agents. 57(4). 106299–106299. 27 indexed citations

Caro, Luzelena, Thomayant Prueksaritanont, Christine Fandozzi, et al.. (2021). Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults. Clinical Drug Investigation. 41(2). 133–147. 5 indexed citations

Li, Haitao, Zhiyuan Yang, Shuqun Zhang, et al.. (2020). A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants. SHILAP Revista de lepidopterología. 1 indexed citations

Caro, Luzelena, Larissa Wenning, Hwa-ping Feng, et al.. (2019). Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. European Journal of Clinical Pharmacology. 75(5). 665–675. 10 indexed citations

Jacobson, Ira M., Fred Poordad, Roberto Firpi-Morell, et al.. (2019). Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study. Clinical and Translational Gastroenterology. 10(4). e00007–e00007. 12 indexed citations

10.

Xiao, Alan, Jennifer A. Huntington, Jianmin Long, & Luzelena Caro. (2018). Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection. International Journal of Antimicrobial Agents. 52(3). 324–330. 7 indexed citations

11.

Maas, Brian M., Antonios O. Aliprantis, Kalpit A. Vora, et al.. (2018). 1384. RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development. Open Forum Infectious Diseases. 5(suppl_1). S424–S425. 10 indexed citations

12.

Feng, Hwa-ping, Luzelena Caro, Christine Fandozzi, et al.. (2018). Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers. The Journal of Clinical Pharmacology. 58(5). 666–673. 14 indexed citations

13.

Marshall, William L., Larissa Wenning, Xiaobi Huang, et al.. (2017). Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment. European Journal of Drug Metabolism and Pharmacokinetics. 43(3). 321–329. 4 indexed citations

14.

Kumada, Hiromitsu, Yoshiyuki Suzuki, Yoshiyasu Karino, et al.. (2016). The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. Journal of Gastroenterology. 52(4). 520–533. 51 indexed citations

15.

Howe, A, Stuart Black, Stephanie Curry, et al.. (2014). Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection. Clinical Infectious Diseases. 59(12). 1657–1665. 33 indexed citations

16.

Manns, Michael P., John M. Vierling, Bruce R. Bacon, et al.. (2014). The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis. Gastroenterology. 147(2). 366–376.e6. 28 indexed citations

17.

Prueksaritanont, Thomayant, Xiaoyan Chu, Raymond Evers, et al.. (2014). Pitavastatin is a more sensitive and selective organic anion‐transporting polypeptide1Bclinical probe than rosuvastatin. British Journal of Clinical Pharmacology. 78(3). 587–598. 144 indexed citations

18.

Mangin, Eric, Wendy W. Yeh, Luzelena Caro, et al.. (2013). Safety and pharmacokinetics of single and multiple oral doses of MK-8742, an HCV NS5A inhibitor, in healthy subjects. Ghent University Academic Bibliography (Ghent University). 3 indexed citations

19.

Lawitz, Eric, Mark Sulkowski, Ira M. Jacobson, et al.. (2013). Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Research. 99(3). 214–220. 26 indexed citations

20.

Marbury, Thomas, Bo Jin, Deborah Panebianco, et al.. (2011). Pharmacokinetics of Oral Dexamethasone and Midazolam When Administered With Single-Dose Intravenous 150 mg Fosaprepitant in Healthy Adult Subjects. The Journal of Clinical Pharmacology. 51(12). 1712–1720. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact